Mylan N.V.

Financial Fraud

SANCTION AMOUNT: $30000000

Defendants: Mylan N.V.

Pharmaceutical company agreed to settle charges of accounting and disclosure failures relating to a Department of Justice probe into whether it overcharged Medicaid by hundreds of millions of dollars for EpiPen, its largest revenue and profit generating product.

Key Docs
Official SEC press release

Find more cases

Named one of the top whistleblower practices/attorneys in the country by The New York Times, Wall Street Journal and NPR

Thank you for submitting some email to us.